Free Trial

Bayer lobbying for Federal labelling laws to overrule state legislation (FT)

HEALTHCARE
  • This isn't a new issue - in early Feb it lost a 11th Circuit appeal on the same grounds & it reportedly had a 3rd circuit appeal outstanding at the time.
  • Our Political Risk team see Republican wins as a positive on legilsation - evidenced by last months' Iowa House of Rep's passing a bill that "manufacturers cannot be held liable for failing to alert people of potential health risks as long as their pesticides have a federally-approved warning label." - Iowa is a GOP supermajority.
  • Re. numbers to watch tomorrow, it had €7b in provisions at end of Q3, 85-90% for Roundup cases. ~2 weeks later it had a major drug failure in late trials & a $1.5b pay-out. As a positive the 2nd/$2.25b pay-out this year should be netted from dividend cut/savings.
  • Its been little support for the name, investors likely disappointed by reports CEO is not looking at a breakup (including of the consumer health or crop science divisions) - likely to get updates/Q&A on that tomorrow.
  • The cash lines (Baa2 Neg, BBB Pos, BBB+ Neg) are unch to 2bps tighter.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.